Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| AstraZeneca PLC | ORPATHYS (savolitinib) + TAGRISSO (osimertinib) - (SAFFRON) | Non-small cell lung cancer (NSCLC) | Phase 3 | Ongoing | oral | Oncology |
| AstraZeneca PLC | Imfinzi (durvalumab), Monalizumab, and Oleclumab - (COAST) | Non-small cell lung cancer (NSCLC) | Phase 2 | Data Released | Intravenous | Oncology |
| AstraZeneca PLC | AZD7442 (STORMCHASER) | COVID-19 (post-exposure prophylaxis) | Phase 3 | Trial Discontinued | Intramuscular | COVID-19 |
| AstraZeneca PLC | CIN-107 - (Spark-PA) | Primary Aldosteronism | Phase 2 | Ongoing | Oral | Endocrinology |
| AstraZeneca PLC | ION449 (AZD8233) - (SOLANO) | Hypercholesterolemia | Phase 2b | Trial Discontinued | Subcutaneous | Cardiology |
| AstraZeneca PLC | Baxdrostat - (Bax24) | Resistant hypertension | Phase 3 | Data Released | Oral | Cardiology |
| AstraZeneca PLC | SOLIRIS (eculizumab) | Neuromyelitis Optica Spectrum Disorder (NMOSD) - children | Phase 2/3 | Trial Planned | Intravenous | Neurology |
| AstraZeneca PLC | IMFINZI (durvalumab) - (CALLA) | Cervical cancer | Phase 3 | Trial Discontinued | Intravenous | Oncology |
